Menopausal hormone therapy: Is there evidence for cardiac protection?
- Nanette K. WengerAffiliated withDivision of Cardiology, Emory University School of MedicineGrady Memorial Hospital, Consultant, Emory Heart and Vascular Center
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Menopausal hormone therapy currently has no evidence-based role in the primary or secondary prevention of cardiovascular disease in women. Repeat analysis of the observational data that corrected for socioeconomic status, educational level, and coronary risk factors; as well as information from randomized clinical trials of menopausal hormone therapy both for healthy women and for women with established coronary heart disease and stroke support this statement. This approach is corroborated by recommendations from the US Food and Drug Administration and the recently released Guidelines for Cardiovascular Prevention for Women of the American Heart Association. The latter Guidelines display the lifestyle and pharmacologic interventions that are appropriate for cardiovascular disease risk reduction for women.
KeywordsCardiovascular disease Estrogen Hormone therapy Progestin Women
- Menopausal hormone therapy: Is there evidence for cardiac protection?
International Urology and Nephrology
Volume 36, Issue 4 , pp 617-623
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- Cardiovascular disease
- Hormone therapy
- Industry Sectors
- Nanette K. Wenger (1) (2)
- Author Affiliations
- 1. Division of Cardiology, Emory University School of Medicine, USA
- 2. Grady Memorial Hospital, Consultant, Emory Heart and Vascular Center, Atlanta, GA, USA